Given the heterogeneity of CLL patients, the current GE-based risk score combined with NRIP1 and TCF7 expression could help in identifying high-risk patients who may benefit from intensive therapeutic strategies and new-targeted treatments. Here, TCF7 is linked to B-cell chronic lymphocytic leukemia.